DAIHRS Group

Duchenne Muscular Dystrophy (DMD) is a severe, X-linked genetic disorder characterized by progressive muscle degeneration and weakness due to a mutation in the gene encoding dystrophin, a critical protein necessary for maintaining the structural integrity of muscle fibers.

Current therapeutic strategies are rapidly evolving, moving beyond solely palliative care to include disease-modifying interventions such as antisense oligonucleotide-mediated exon skipping, which aims to restore a partially functional dystrophin protein.

For decades, the standard of care for DMD focused primarily on glucocorticoid corticosteroids, which help slow the decline in muscle strength and function, and multidisciplinary support involving physical therapy, respiratory management, and cardiac care. However, the true breakthrough lies in targeted genetic and molecular approaches. **Exon skipping** drugs utilize antisense oligonucleotides (ASOs) that bind to specific sequences of the dystrophin pre-mRNA, effectively hiding a mutated exon from the cellular splicing machinery. If the reading frame is restored, a shorter, but more functional, version of the dystrophin protein can be produced, potentially converting the phenotype towards the less severe Becker muscular dystrophy. A more recent and potentially curative approach involves **gene therapy**, which uses viral vectors, such as adeno-associated virus (AAV), to deliver a micro-dystrophin gene (a truncated, smaller version of the full gene that fits within the viral vector) directly to muscle cells. While these therapies are still undergoing rigorous evaluation for long-term efficacy and safety, particularly concerning immune response and systemic delivery, they represent the frontier of precision medicine for this debilitating condition. [Image of Dystrophin protein in muscle fiber]